Two senior physicians who co-founded Fullerton Healthcare Corporation have been penalised with a combined fine of S$160,000 for orchestrating a scheme to falsify entertainment expense claims in Singapore. Daniel Chan Pai Sheng and Michael Tan Kim Song, both aged 52, pleaded guilty to multiple counts of account falsification on July 8, with the district judge imposing fines on July 10. The case reveals how internal fraud can penetrate well-established healthcare enterprises, raising questions about corporate governance and financial oversight in the region's private medical sector.
Chan received the heavier penalty of S$135,000 after admitting to five counts of falsification. The inflated claims he orchestrated totalled over S$336,000, though actual documented expenditures amounted to merely S$125,000, creating a discrepancy exceeding S$211,000. Tan, meanwhile, was fined S$25,000 for a single count of falsification involving an approximately S$82,000 claim when genuine expenses stood at just over S$42,000. Both men acknowledged their wrongdoing, though neither personally benefitted from the fraudulent transactions—a detail that distinguishes this case from typical embezzlement scenarios.
The beneficiary of the scheme was Collin Chiew, a 58-year-old businessman who previously served as chief executive of insurance broker Aon Singapore from January 2015 through July 2018. Court documents indicate that Chiew approached Chan in 2015 seeking financial assistance to support his children and purchase property. Rather than extending a direct loan, Chan and Tan devised an elaborate method to extract funds from their own company through fabricated entertainment expenses. Chiew's current legal status remains unclear, with prosecutors declining to prosecute him on graft-related charges despite his apparent role as the intended recipient.
The fraudulent scheme operated with methodical precision across multiple jurisdictions. Beginning around 2015, Chan regularly travelled to Hong Kong twice monthly to facilitate business development for Fullerton Healthcare Corporation's operations there. Before departing Singapore, he would request false or inflated karaoke establishment receipts from David Sin, another co-founder, who coordinated with an accomplice named Tei Chu Pink. During Hong Kong visits, Chan would socialise at these venues with Sin and Tei while meeting prospective investors, subsequently obtaining the doctored receipts to bring back to Singapore.
The mechanics of the deception involved a carefully choreographed performance of legitimacy. On some occasions, Chan made genuine partial payments at the karaoke establishments using personal cash or credit cards, creating a veneer of authenticity. Other times, he made no payments whatsoever, yet the inflated receipts were processed as though full transactions had occurred. This variance in actual expenditures masked the pattern from casual auditing. Upon returning to Singapore, Chan distributed these falsified receipts to designated personnel within Fullerton Healthcare Corporation and its subsidiary Fullerton Health China, who incorporated them into official financial records and processing systems.
Tan's involvement extended beyond mere knowledge of the scheme. Prosecutors demonstrated that multiple falsified claims proceeded with his explicit awareness, and in at least one 2016 instance, he actively participated in conspiring with Chan and Sin to fabricate an entertainment expense. This level of participation from a company co-founder suggests systematic rather than isolated fraud, potentially indicating weak internal controls at an enterprise handling both healthcare services and insurance claim processing. The company's dual operational nature—acting as both a provider and a claims facilitator—created multiple touch points where fraudulent entries could be inserted into financial systems.
Third co-founder David Sin had previously faced similar consequences in August 2025, when he pleaded guilty to six counts of falsification and received an identical S$160,000 fine. His involvement in sourcing and preparing the false receipts positioned him as a critical operational component of the scheme. The sequential prosecution of three company principals suggests a comprehensive investigation into organisational wrongdoing rather than isolated individual misconduct. Notably, both Tan and Chan have since relinquished their respective positions—Tan as director of Fullerton Healthcare Group and Chan as president of Fullerton Health China—indicating that the company has begun remedial corporate restructuring.
Prosecutors initially pursued graft-related corruption charges against both men, reflecting the scheme's fraudulent nature and potential breach of fiduciary duties owed to shareholders and stakeholders. However, the prosecution withdrew these charges on July 10 through a mechanism known as discharge not amounting to acquittal. This prosecutorial discretion permits the authorities to reinstitute charges if additional evidence surfaces in future investigations. The strategic decision to pursue only the more straightforward falsification counts suggests prosecutors identified sufficient evidence for conviction on those charges while assessing corruption charges as potentially more complex or requiring additional investigation.
For Malaysian readers and Southeast Asian observers, this case underscores vulnerabilities in corporate financial systems across the region. Fullerton Healthcare Corporation operates in multiple jurisdictions including Singapore, China, and serves regional clients through insurance claim processing services. The scheme exploited the complexity of cross-border business operations, leveraging international travel as cover for financial manipulation. Healthcare enterprises managing both clinical operations and financial services face heightened responsibility to implement robust segregation of duties, particularly when founders maintain operational control over financial approval processes.
The case carries implications for corporate governance frameworks throughout Southeast Asia, where family-founded and founder-led enterprises remain prevalent. The involvement of the company's co-founders raises concerns about board independence and audit committee oversight. When senior founders personally direct financial operations without adequate external scrutiny, mechanisms for detecting or preventing fraud become compromised. This situation demonstrates why many jurisdictions increasingly mandate independent board representation and mandatory financial audits, protections that may not have been sufficiently robust at Fullerton Healthcare Corporation.
The scheme's duration and scale also merit attention from regulatory bodies overseeing healthcare and insurance sectors in the region. The fraudulent claims spanned multiple years and exceeded S$200,000, yet apparently remained undetected until formal investigation. This suggests potential gaps in either internal audit procedures or external regulatory oversight capabilities. Financial institutions and healthcare enterprises processing substantial sums must implement regular forensic auditing protocols and anomaly detection systems that flag unusual expense patterns or geographical concentrations of claims.
Looking forward, the case will likely influence how investors and business partners evaluate governance practices at regional healthcare firms. Fullerton Healthcare Corporation's ability to recover from this reputational damage will depend on implementing transparent financial controls, establishing independent audit functions, and demonstrating commitment to preventing recurrence. The prosecution's decision to proceed with falsification charges while exercising prosecutorial discretion on corruption counts provides a pathway for the company to address the financial crimes without facing the most severe penalties, potentially allowing operational continuity under reformed management structures.
